{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "BWIN",
  "name": "The Baldwin Insurance Group, Inc.",
  "url": "https://orbyd.app/dossiers/BWIN/",
  "json_url": "https://orbyd.app/dossiers/BWIN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M, mid-single-digit organic) is the binary that either funds the deal math or collapses it.",
  "invalidation_trigger": "A weekly close below $24 unwinds the take-private premium; a 2026-07-30 print missing the $485–490M guide or organic below mid-single digits breaks the fundamental leg.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "fintech-consumer-credit"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Analyst PTs: UBS Buy $35 (2026-06-09, pre-rumor), JPM Overweight $28 (2026-06-22), BMO Market Perform $25 (2026-06-23). Spot $28.41 (2026-07-02), 52-wk $15.88–$43.64.",
    "Q2 2026 results 2026-07-30 after close, 5:00pm ET call (BusinessWire 2026-06-25). Company guide: revenue $485–490M, mid-single-digit organic, second-half acceleration. Binary — avoid fresh sizing into the print.",
    "Take-private remains rumor-stage: Insurance Insider 2026-06-18 (Ardea retained to weigh options incl. PE-financed take-private). Company declined comment. Confirmation or denial is a gap catalyst in either direction.",
    "Deal-math anchors circulating in sell-side work: BMO models 15%+ IRR at a $25 takeout; broader street commentary supports $28.50–$30.00/sh with a ~7.7% year-one FCF yield to a buyer. Spot $27.25 sits inside that band — most of the plausible premium is already paid.",
    "PT ladder rising while price falls: KBW Outperform $31 (2026-07-08), Wells Fargo Equal-Weight $27 (2026-07-09), JPM Overweight $30 (2026-07-13), BMO Market Perform $25 (2026-06-23), UBS Buy $35 (2026-06-09, pre-rumor). Consensus ~$30.4–30.9, low $23, high $40.",
    "Anthropic enterprise expansion announced 2026-05-04 — firm-wide Claude deployment; Baldwin is the first named enterprise customer of Anthropic's JV with Blackstone, Goldman Sachs, Hellman & Friedman, General Atlantic and Sequoia. Feeds the 3B30 margin story but is not yet a quantified P&L line.",
    "Q1 2026 (2026-05-04): revenue $532.2M +29% YoY, adj EBITDA $137.2M +21%, adj EPS $0.63, organic only 2% YoY and decelerating since Q3 2025. Leverage ~4.1x. TTM revenue $1.62B, GAAP EPS -$0.61, forward P/E ~12.5.",
    "Conflicting price prints across data vendors around the 2026-06-22 rumor pop (one source cites a $20.24 close, another a base near $23.27). Treat the pre-rumor shelf as a $23–24 zone rather than a single tick."
  ],
  "body_markdown": "## Current Thesis\nTwo weeks ago this was a take-private re-rating running ahead of its fundamentals. It is now a take-private re-rating that has stopped going up. Price closed $27.25 on 2026-07-17, below the $28.41 print of 2026-07-02, while the sell-side ladder climbed in the opposite direction — Keefe Bruyette to $31 on 2026-07-08, Wells Fargo to $27 on 2026-07-09, JPMorgan to $30 on 2026-07-13. Rising targets into falling price is the market declining to pay for a deal nobody has signed. Insurance Insider's 2026-06-18 report that Ardea was retained to weigh options remains the entire basis of the premium; Baldwin has not commented since. Eleven days out sits a Q2 print (2026-07-30, after close) against a company guide of $485–490M revenue and mid-single-digit organic — the number that either validates the leverage math a private buyer would underwrite, or exposes the premium as a rumor with no floor beneath it.\n\n## Bull Case\n- **Deal economics land where the stock trades.** BMO (2026-06-23) modelled a 15%+ IRR to a buyer at a $25 takeout; wider street work supports $28.50–$30.00/share on roughly a 7.7% year-one free-cash-flow yield. A confirmed process priced at the top of that band is a ~10% gap from spot.\n- **JPMorgan is the most committed bull and keeps adding.** Pablo Singzon moved Neutral→Overweight on 2026-06-22 calling a take-private \"credible,\" then raised the target again to $30 on 2026-07-13 — an escalation, not a maintenance note.\n- **Guidance implies the organic trough is behind.** Management guided Q2 to mid-single-digit organic with second-half acceleration, against the 2% posted in Q1 2026. A print that delivers mid-single digits converts the deceleration narrative into an inflection.\n- **The AI leg is real and early.** The 2026-05-04 Anthropic expansion deploys Claude firm-wide across advisor, client-experience and operational workflows, following months of piloted deployment with measured productivity gains. Baldwin is the first named enterprise customer of Anthropic's JV with Blackstone, Goldman Sachs, Hellman & Friedman, General Atlantic and Sequoia — which is also a soft signal of PE-sponsor familiarity with the asset.\n- **3B30 gives the multiple a fundamental anchor.** The program set in Q3 2025 targets $3B revenue and 30% margins by 2029; CAC Group synergies are ~80% actioned, with $34M of cost actions underway.\n\n## Bear Case\n- **The premium is decaying in real time.** Down ~4% over two weeks while three brokers raised targets. When price refuses a rising PT ladder, the marginal buyer has already bought.\n- **Nothing is signed and the company is silent.** No confirmed process, no exclusivity, no bidder named. A lapsed or denied review takes the stock back toward the $23–24 pre-rumor shelf without an intervening level.\n- **Organic growth has decelerated every quarter since Q3 2025.** Q1 2026 printed 2% (5% \"normalized\"). The multiple re-rated on M&A speculation while the growth engine slowed — a mismatch a soft Q2 resolves violently.\n- **Leverage ~4.1x cuts both ways.** It is what makes the LBO plausible and what caps public upside; a credit-spread widening hits the equity and the buyout math simultaneously.\n- **Still GAAP loss-making.** TTM EPS -$0.61 against a 2025 net loss of $33.8M. The story runs entirely on adjusted EBITDA and synergy execution.\n- **Analyst dispersion is wide.** Targets span $23 to $40 with consensus near $30.4. That spread is the market pricing two different companies — a deal and a no-deal — not a converged view.\n\n## Setup & Price Structure\n- $27.25 (2026-07-17) inside a 52-week range of $15.88–$43.64: roughly 38% below the high, 72% above the low. Market cap ~$2.7B, forward P/E ~12.5 on $1.62B TTM revenue.\n- The rally off the 2026-06-18 report has rolled into a two-week drift lower. The structure is a post-event fade, not a base — there is no higher low yet to buy against.\n- The $23–24 area is the pre-rumor shelf; everything above it is deal optionality. Note that price prints around the 2026-06-22 pop diverge across vendors, so treat the shelf as a zone.\n- No cluster confirmation. Consolidator-broker peers are not breaking out in sympathy; this is an idiosyncratic event trade with no theme tailwind carrying it.\n- Beginner-trap read: buying a decaying M&A premium eleven days ahead of a binary print, on a name whose sell-side targets are rising precisely because it already moved. Chasing the analyst ladder here is buying what has already been priced.\n\n## Catalyst Calendar (next 30 days)\n\n- **Any date, unscheduled** — confirmation, denial, or lapse of the Ardea process. This is a gap event in both directions and the single largest variable in the name.\n- **~2026-08-13 (est.)** — Form 10-Q filing, typically within two weeks of the print; segment organic detail and leverage covenant disclosure.\n\n## Elapsed catalysts\n\n- **2026-07-30 (confirmed)** — Q2 2026 results after market close, 5:00pm ET call (BusinessWire, 2026-06-25). Guide: revenue $485–490M, mid-single-digit organic, H2 acceleration. Watch organic, margin trajectory, CAC cross-sell, and any strategic-review language on the call. *(passed 10d ago)*\n- **Rolling** — further sell-side revisions. Five houses have moved since 2026-06-22; a downgrade or PT cut after the print would confirm the premium is unwinding. *(passed 48d ago)*\n\n## What Would Change Our Mind\n- A weekly close below $24 removes the deal premium entirely and puts the name back on fundamentals that do not support the current multiple.\n- A 2026-07-30 print delivering mid-single-digit organic **plus** explicit management confirmation of an active strategic process would flip this from a fading rumor to a two-legged setup worth real size — that combination is the only path to upgrading conviction here.\n- An announced signed transaction above $30 resolves the trade at the top of the modelled band; an announced deal at $25 caps it below spot and is a negative outcome from here.\n- A public denial or a report that the process has been shelved sends this straight to the pre-rumor shelf; there is no fundamental bid between $27 and $24.\n\n## Correlation Notes\n- Trades with the insurance-brokerage consolidation complex (AJG, BRO, MMC, RYAN) on organic-growth and P&C pricing datapoints, but the deal premium has decoupled it from that group since 2026-06-18. Peer organic prints in the same reporting window are the cleanest read-through to Baldwin's own number.\n- Rate-sensitive through ~4.1x leverage. Widening high-yield spreads compress both the equity and the financeability of a sponsor bid — this is the macro channel that kills the thesis without any company-specific news.\n- The Anthropic relationship links it loosely to the enterprise-AI-adoption narrative, though the P&L contribution is unquantified and the market is not currently paying for it.\n- P&C pricing softness is the sector-level headwind on organic; a further deceleration in commercial rates pressures the whole group and removes the \"improving fundamentals\" premise underpinning the JPMorgan upgrade.",
  "first_seen": "2026-06-30",
  "last_analyzed": "2026-07-20T07:29:00+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}